AlphAIalphai — Financial news for AI agents
Stock TitanMAR 33 min read$ATYR

ATYR Financials: Income Statement, Balance Sheet & Cash Flow

This article provides a detailed financial overview of Atyr Pharma Inc (ATYR), including its income statement, balance sheet, and cash flow statement, along with key financial ratios. It highlights the company's financial health signals, annual and quarterly metrics, and frequently asked questions about its performance. The analysis indicates weak overall financial health with low profitability and negative cash flow, despite strong liquidity and low leverage.

Original reporting
Stock Titan
Published Mar 3, 2026, 8:51 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Mar 3, 2026, 8:56 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
ATYR Financials: Income Statement, Balance Sheet & Cash Flow — source image
Source · Stock Titan
Decision brief

The 30-second read

$ATYRBearishLow
01

Why it matters

Financial weakness may lead to further stock decline, affecting investor confidence and sector perception.

02

Market read

Financial data indicates limited short-term trading opportunities; more relevant for long-term risk assessment.

03

What to watch

Potential upcoming catalysts or partnership news not reflected in current financials could alter outlook.

Timing: Limited short-term trading relevance; primarily long-term concern.

Background

Recent financial statements reveal ongoing challenges for ATYR, including low profitability and negative cash flow, despite liquidity.

Company-level read

Ticker impact

$ATYRBearishMedium confidence
Context

High relevance due to direct financial data impact.

Expected impact

Potential further decline in stock price due to ongoing financial struggles.

Evidence & confidence

The analysis is based on recent financial reports indicating poor profitability and cash flow issues, which historically correlate with downward price movements. However, lack of current market price data limits precision.

Market effects

Sector

Weak financials in biotech/life sciences sector may pressure sector indices.

Regional

Limited regional impact; company-specific issue.

Global

Minimal global market relevance; focused on company fundamentals.

Counterpoint

What could challenge this read

If company management implements strategic turnaround, stock could stabilize or improve over the medium term.

Key entities

  • Company
    Atyr Pharma Inc

    Biotech company focusing on rare disease treatments.

Read at source← All news

Related articles

SEP 2
$UPCMed

6 After-Hours Healthcare Gainers: Universe Pharma, BioAffinity, Modular Medical, Telix Pharma & More

Universe Pharmaceuticals (UPC) rose 34.89% after-hours due to multiple Schedule 13G filings. BioAffinity (BIAF) explores new uses for its CyPath Lung test, up 3%. Modular Medical (MODD) gained 7% after announcing a product launch. MAIA (MAIA) rose 6% following an insider purchase. Telix (TLX) completed a Phase 3 study, up 2.21%. aTyr Pharma (ATYR) awaits FDA response, up 4%.

rttnews.com2 min
AUG 7
$ATYRMed

aTYR PHARMA INC (ATYR): Results of Operations and Financial Condition

aTYR PHARMA INC (ATYR) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Contact: Ashlee Dunston Sr. Director, Investor Relations and Public Affairs adunston@atyrpharma.com aTyr Pharma Announces Second Quarter 2026 Results, Program Prioritization and Corporate Restructuring to Support Efzofitimod Program in ILD Company awaiting comments f

SEC EDGAR 8-K4 min
SEP 2
High

BofA downgrades Amrize to underperform, cuts price target on slower growth outlook

Bank of America downgraded Amrize to Underperform, cutting its price target to $40 from $50 due to slower earnings growth, market risks, and valuation concerns. The brokerage lowered its 2027-28 adjusted EBITDA and EPS estimates, citing stable U.S. cement prices, Canadian demand pressure from U.S. tariffs, and vulnerable roofing margins. BofA forecasts adjusted EBITDA growth of 3% and adjusted EPS growth of 6% annually over 2026-28, excluding large acquisitions. The bank also trimmed its buildin

investing.com2 min
SEP 2
$NIOMed

J.P. Morgan cuts NIO to Neutral, slashes price target on weak demand outlook

J.P. Morgan downgraded NIO (NIO) to Neutral, cutting its price target to $4.50 from $7.00 due to weak demand in China's passenger-vehicle market and intensifying competition. The brokerage cited cost pressures and moderating growth, forecasting lower revenue and earnings. NIO's Q2 vehicle gross margin was 18.5%, but further pressure is expected. J.P. Morgan prefers BYD and Geely among Chinese automakers.

investing.com2 min